This study reveals the mechanism by which anti-PD-1 therapy induces rapid innate immune responses in people living with HIV, finding that sustained activation of interferon-stimulated genes (ISGs) is closely associated with HIV reservoir reduction, providing key biomarkers and intervention targets for functional HIV cure strategies.
Literature Overview
This paper, 'Anti-PD-1 Therapy Promotes HIV Reservoir Decline by Activating Innate Antiviral Immunity,' published in Nature Medicine, reviews and summarizes the association between viral reservoir dynamics and host immune responses in HIV-positive individuals with cancer who received anti-PD-1 immunotherapy. Through multi-omics longitudinal analysis, the study systematically characterizes immune reprogramming events occurring within 24 hours of treatment, revealing rapid activation of type I interferon, antiviral restriction factors, and Toll-like receptor (TLR) signaling pathways, and confirming that these early immune features can predict subsequent significant declines in the HIV reservoir. This work provides critical evidence for understanding the mechanisms of immune checkpoint blockade in HIV cure strategies.Background Knowledge
Although antiretroviral therapy (ART) effectively suppresses HIV replication, the virus persists in CD4+ T cells expressing immune checkpoint molecules such as PD-1, forming a long-lived reservoir that hinders eradication. Immune checkpoint blockade (ICB), such as anti-PD-1 antibodies, has been widely used in cancer treatment. Recent studies have shown that ICB in HIV-infected individuals can activate HIV-specific T cells and promote viral transcription, suggesting its potential for a 'shock and kill' strategy. However, it remains unclear which patients benefit from this approach and what specific immune mechanisms drive reservoir reduction. Previous studies have largely focused on T-cell functional restoration, with limited systematic analysis of the role of the innate immune system. This study fills this gap by integrating single-cell transcriptomics, plasma cytokines, and viral load data, revealing that anti-PD-1 therapy not only acts on T cells but also rapidly activates myeloid cells and type I interferon pathways, forming a coordinated immune network for eliminating infected cells. This finding expands our understanding of ICB mechanisms and highlights the critical role of innate immunity in HIV cure, providing a theoretical basis for developing personalized intervention strategies based on immune profiling.
Research Methods and Experiments
The study is based on the CITN-12 clinical trial (NCT02595866), which prospectively enrolled 30 HIV-positive individuals with cancer receiving pembrolizumab. A multi-omics longitudinal analysis was conducted. Peripheral blood samples were collected before treatment (C01D01), at 24 hours (C01D02), day 8 (C01D08), and at the end of treatment (EOT). Analyses included whole-blood transcriptome sequencing, single-cell RNA sequencing (scRNA-seq), plasma cytokine profiling, and assessment of HIV viral load (RNA) and reservoir size (DNA). Gene set enrichment analysis (GSEA) and SLEA scoring were used to construct immune modules. Combined with CIBERSORT and NicheNet analyses, the study systematically dissected dynamic changes in immune cell subsets and intercellular communication. The SCimilarity platform was used to compare the identified transcriptional signatures against over 1,000 public single-cell datasets to assess their generality across disease states.Key Conclusions and Perspectives
Research Significance and Prospects
This study is the first to systematically elucidate how anti-PD-1 therapy promotes HIV reservoir decline in infected individuals by activating innate immune pathways, proposing sustained ISG activation as a potential biomarker for predicting treatment response. This finding provides new theoretical support for the 'shock and kill' strategy, emphasizing the need to target both adaptive and innate immune systems for more effective viral clearance.
The results suggest that pre-screening patients for a pre-existing ISG-high immune state may improve the success rate of immunotherapy. Future studies could explore combining TLR agonists or IFN inducers with anti-PD-1 therapy to enhance antiviral immunity and improve outcomes in HIV functional cure strategies. Additionally, the multi-omics analytical framework established in this study can be applied to other immune intervention studies, advancing the development of personalized HIV cure approaches.
Conclusion
This study uses multi-omics longitudinal analysis to uncover the key immune mechanisms by which anti-PD-1 therapy induces HIV reservoir decline in infected individuals. It demonstrates that rapid innate immune reprogramming occurs within 24 hours of treatment, characterized by significant activation of type I interferon signaling, antiviral restriction factors, and TLR pathways, along with decreased TGFβ levels. Patients can be stratified into responder (ISGhi) and non-responder (ISGlo) groups based on baseline ISG module expression, with the former showing significant HIV reservoir reduction by the end of treatment. Single-cell analysis further confirms the expansion of ISG-high monocytes and effector CD8+ T cells post-treatment, with IFNβ and IFNγ identified as key upstream drivers of this phenotype. In vitro experiments show that IFN and TLR agonists effectively suppress HIV infection. This work not only clarifies the mechanism of anti-PD-1 in HIV cure but also identifies immune biomarkers predictive of treatment response, providing a critical foundation for developing personalized immune interventions and advancing HIV functional cure research into the era of precision medicine.
